Agilent Technologies Revenue Climbs 7% to $1.80B in Q1 FY2026

Agilent Technologies (NYSE: A), a life sciences and diagnostics equipment maker, reported revenue of $1.80 billion for the three months ending January 31, 2026, up 7% from $1.68 billion in the same quarter a year earlier. Net income declined 4% to $305 million from $318 million in the prior-year period. Read more earnings reports.

Operating income for the quarter totaled $442 million, up from $422 million a year earlier. Operating expenses surged to $89 million from $46 million, driven by higher selling, general and administrative costs, which rose to $476 million from $410 million.

Cost of goods sold increased to $852 million from $782 million. Research and development expenses edged up to $117 million from $113 million.

The company generated $268 million in cash from operations, down sharply from $431 million in the year-ago quarter. Cash used in investing activities totaled $93 million, roughly flat with $94 million a year earlier. Financing activities consumed $222 million, compared to $180 million in the prior-year period.

Balance Sheet and Capital Position

Total assets stood at $12.81 billion as of January 31, up from $12.73 billion at the end of October 2025. Cash and cash equivalents declined to $1.76 billion from $1.79 billion at the prior quarter end. Accounts receivable rose to $1.52 billion from $1.49 billion, while inventory increased to $1.06 billion from $1.03 billion.

Long-term debt remained unchanged at $3.05 billion. Total liabilities fell to $5.91 billion from $5.99 billion, while stockholders' equity increased to $6.91 billion from $6.74 billion.

Earnings Per Share and Shares Outstanding

Diluted earnings per share came in at $1.07, down from $1.11 in the year-ago quarter. Basic earnings per share were $1.08, compared to $1.12 a year earlier. Weighted average diluted shares outstanding totaled 284 million, down from 287 million in the prior-year period. Common shares outstanding at quarter end were 282.7 million, down from 283.1 million at the end of October.

Segment Performance

The Life Sciences and Applied Markets segment recorded revenue of $679 million, up from $647 million a year earlier. The Diagnostics and Genomics segment posted revenue of $758 million, up from $696 million. The Agilent CrossLab segment reported revenue of $361 million, up from $338 million.